Tag:

Isconova

Latest Headlines

Latest Headlines

Novavax makes $30M bid for adjuvant business

June 5, 2013 | By
The deal has the backing of the three largest shareholders, and Novavax expects to close the takeover by the end of next month. With the deal, Novavax gets ownership of a proprietary adjuvant technology it can use in vaccine candidates for pandemic flu, rabies, respiratory syncytial virus in the elderly, foot-and-mouth and other diseases.

FhCMB nabs up to $9.9M from NIH for anthrax vaccine research

December 6, 2012 | By
Fraunhofer Center for Molecular Biotechnology could receive up to $9.9 million in funding from NIH's National Institute of Allergy and Infectious Diseases to develop the next generation of anthrax vaccines.

Sweden's Isconova buys Nordic Vaccine

May 4, 2011 | By
Isconova has purchased the Danish drug delivery and adjuvants company Nordic Vaccine for over 4 million Swedish kroner, or $663,000. "The acquisition of Nordic Vaccine is in line with Isconova's

Isconova gets $5.2M for vaccine work

FierceBiotech | June 27, 2008
Sweden's Isconova has secured financing of 30 million Swedish kronor ($5.2 million) from InnovationsKapital for its work in vaccine adjuvant technology.
Related Tags

Isconova Press Releases

  • Isconova Strengthens Product and Patent Portfolio, Acquires the Assets of Nordic Vaccine A/S
Press Releases
  • FDA Classifies St. Jude Medical Field Action for 447 of the Company's Optisure High Voltage Leads as a Class 1 Advisory in the U.S.
  • Ceva and Zoion Pharma Announce Collaboration to Develop Epithelial Sodium Channel Blockers to Treat Veterinary Ocular Surface Diseases
  • Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
  • Minnesota's Medical Alley Raises Record-Setting $434.9 Million in 2015
  • Shire Completes Acquisition of Dyax
  • More Press Releases
Sponsored Links